好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Seizure Outcomes after Antiparasitic Treatment in Patients with Neurocysticercosis: Systematic Review and Meta-analysis
Epilepsy/Clinical Neurophysiology (EEG)
P6 - Poster Session 6 (5:00 PM-6:00 PM)
11-007

This review aimed to synthesize existing evidence on the efficacy of antiparasitic therapy in reducing seizure recurrence among patients with neurocysticercosis.
Neurocysticercosis is a leading cause of acquired epilepsy in endemic regions and remains the most common parasitic infection of the central nervous system (CNS). Recent evidence suggests that antiparasitic treatment, used in combination with corticosteroids, may reduce seizure frequency in some patients.
We conducted a systematic review and meta-analysis according to PRISMA guidelines. Literature searches were performed in PubMed, Embase, Global Index Medicus, Web of Science, CINAHL, and Scielo from inception to August 8, 2025. We included randomized controlled trials (RCTs) and non-randomized controlled trials (NRCTs) comparing antiparasitic treatment (albendazole and/or praziquantel) with placebo and/or standard therapy. Primary outcome was seizure recurrence within 12 months of follow-up. Subgroup analyses were performed according to age group, number of lesions and use of corticosteroid. Pooled effect estimates were calculated using a fixed-effects meta-analysis.
A total of 680 articles were screened, of which 38 studies met the eligibility criteria, including 3,662 patients. The meta-analysis found no significant difference between albendazole and placebo in seizure recurrence within 12 months of follow-up (20 studies; RR = 0.75, 95% CI 0.50–1.10; p = 0.14). However, subgroup analyses revealed that albendazole significantly reduced seizure recurrence in children (6 studies; RR = 0.45, 95% CI 0.31–0.65; p < 0.001) and in patients with single enhancing lesions (8 studies; RR = 0.59, 95% CI 0.40–0.86; p = 0.01), while concomitant corticosteroid use did not demonstrate a significant effect (5 studies; RR = 0.62, 95% CI 0.33–1.16; p = 0.13).

Our findings indicate that albendazole did not significantly reduce seizure recurrence, subgroup analyses show relevant benefit in children and patients with single enhancing lesions.
Authors/Disclosures
Sharon Sofia Guevara Lazo
PRESENTER 		Mrs. Guevara Lazo has nothing to disclose.
Lucero Brigitte Diaz Capcha Miss Diaz Capcha has nothing to disclose.
Andrea B. Lagunas Gutiérrez, Med Miss Lagunas Gutiérrez has nothing to disclose.
Maricielo Huayaney Rojas, Sr., MBBS Mrs. Huayaney Rojas has nothing to disclose.
Arantxa N. Sanchez Boluarte, MD, MPH (UNIVERSIDAD PERUANA CAYETANO HEREDIA) Dr. Sanchez Boluarte has received research support from NIH Fogarty International Center .
Wilfor Aguirre-Quispe (INCN) Wilfor Aguirre-Quispe has nothing to disclose.
Sofía S. Sánchez Boluarte, MD (Universidad Cesar Vallejo) The institution of Dr. Sánchez Boluarte has received research support from NIH.
William O. Tatum IV, DO, FAAN (Mayo Clinic) Dr. Tatum has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bioserenity. Dr. Tatum has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Natus. Dr. Tatum has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Tatum has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Tatum has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Defense Law Firm on behalf of a patient with epilepsy with funds donated to the Epilepsy Foundation of America. The institution of Dr. Tatum has received research support from Esai. The institution of Dr. Tatum has received research support from Mayo Clinic. The institution of Dr. Tatum has received research support from Liva Nova. The institution of Dr. Tatum has received research support from Engage Pharmaceuticals. The institution of Dr. Tatum has received research support from Xenon. Dr. Tatum has received intellectual property interests from a discovery or technology relating to health care. Dr. Tatum has received publishing royalties from a publication relating to health care. Dr. Tatum has received publishing royalties from a publication relating to health care. Dr. Tatum has received publishing royalties from a publication relating to health care. Dr. Tatum has a non-compensated relationship as a AAN Section Chair of Clinical Neurophysiology with AAN that is relevant to AAN interests or activities.